Agios Pharma (AGIO)
31.82
+2.36 (8.01%)
Upcoming Events
Latest Headlines
Agios Pharma (AGIO) PT Raised to $54 at H.C. Wainwright
June 15, 2026 6:49 AM - StreetInsider
Agios presents Phase 3 sickle cell disease trial results at EHA conference
June 13, 2026 9:00 AM - StreetInsider
Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
June 13, 2026 9:00 AM - Globe NewsWire
Agios Pharma (AGIO) PT Lowered to $31 at JPMorgan
June 11, 2026 8:38 AM - StreetInsider
Agios licenses blood disorder drug from Oscotec for $25 million upfront
June 1, 2026 5:00 AM - StreetInsider
Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib
June 1, 2026 5:00 AM - Globe NewsWire
Agios Pharma (AGIO) PT Lowered to $59 at Leerink
May 29, 2026 10:42 AM - StreetInsider
Agios halts tebapivat development for blood cancer indication
May 29, 2026 7:00 AM - StreetInsider
Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes
May 29, 2026 7:00 AM - Globe NewsWire
PYRUKYND gets EU approval for thalassaemia treatment
May 22, 2026 10:18 AM - StreetInsider
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia
May 22, 2026 10:18 AM - BizWire
Agios receives European approval for PYRUKYND to treat thalassemia
May 22, 2026 9:15 AM - StreetInsider
Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia
May 22, 2026 9:15 AM - Globe NewsWire
Form SCHEDULE 13G/A AGIOS PHARMACEUTICALS, Filed by: ARMISTICE CAPITAL, LLC
May 15, 2026 11:02 AM - SEC Filing
Agios submits application for accelerated approval of mitapivat in sickle cell
May 12, 2026 9:32 AM - StreetInsider
Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease
May 12, 2026 9:31 AM - Globe NewsWire
Agios to present mitapivat data at EHA 2026 conference
May 12, 2026 9:30 AM - StreetInsider
Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias
May 12, 2026 9:30 AM - Globe NewsWire
Form SCHEDULE 13G AGIOS PHARMACEUTICALS, Filed by: Lynx1 Capital Management LP
May 6, 2026 4:22 PM - SEC Filing
Agios Pharma (AGIO) PT Lowered to $36 at Truist Securities
April 30, 2026 7:10 AM - StreetInsider
Form SCHEDULE 13G AGIOS PHARMACEUTICALS, Filed by: VANGUARD CAPITAL MANAGEMENT LLC
April 29, 2026 4:40 PM - SEC Filing
Form 10-Q AGIOS PHARMACEUTICALS, For: Mar 31
April 29, 2026 9:31 AM - SEC Filing
Form 8-K AGIOS PHARMACEUTICALS, For: Apr 29
April 29, 2026 6:33 AM - SEC Filing
Agios Pharma (AGIO) Tops Q1 EPS by 12c
April 29, 2026 6:30 AM - StreetInsider
Agios Reports First Quarter 2026 Financial Results and Provides Business Update
April 29, 2026 6:30 AM - Globe NewsWire
Form ARS AGIOS PHARMACEUTICALS, For: Dec 31
April 24, 2026 4:09 PM - SEC Filing
Form DEFA14A AGIOS PHARMACEUTICALS,
April 24, 2026 4:03 PM - SEC Filing
Form DEF 14A AGIOS PHARMACEUTICALS, For: Jun 18
April 24, 2026 4:02 PM - SEC Filing
Agios Pharma (AGIO) PT Lowered to $41 at BofA Securities
April 21, 2026 8:48 AM - StreetInsider
Agios Pharma (AGIO) PT Lowered to $50 at H.C. Wainwright
April 21, 2026 6:40 AM - StreetInsider
Leerink Partners on Agios Pharma (AGIO): NVO's Ph3 trial results likely to pressure shares
April 20, 2026 10:14 AM - StreetInsider
Agios Pharmaceuticals stock tumbles 25% after Novo data
April 20, 2026 9:52 AM - StreetInsider
Form 4 AGIOS PHARMACEUTICALS, For: Apr 02 Filed by: Burns James William
April 6, 2026 4:12 PM - SEC Filing
Form 4 AGIOS PHARMACEUTICALS, For: Apr 02 Filed by: Gheuens Sarah
April 6, 2026 4:10 PM - SEC Filing
Form 4 AGIOS PHARMACEUTICALS, For: Apr 02 Filed by: Jones Cecilia
April 6, 2026 4:09 PM - SEC Filing
Form 4 AGIOS PHARMACEUTICALS, For: Apr 02 Filed by: Milanova Tsveta
April 6, 2026 4:08 PM - SEC Filing
Form 4 AGIOS PHARMACEUTICALS, For: Apr 02 Filed by: Viswanadhan Krishnan
April 6, 2026 4:06 PM - SEC Filing
Form 4 AGIOS PHARMACEUTICALS, For: Apr 02 Filed by: Goff Brian
April 6, 2026 4:05 PM - SEC Filing
Agios Pharma (AGIO) PT Raised to $36 at JPMorgan
April 6, 2026 7:45 AM - StreetInsider
Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET
April 6, 2026 7:00 AM - Globe NewsWire
Form 144 AGIOS PHARMACEUTICALS, Filed by: Goff Brian
April 2, 2026 4:10 PM - SEC Filing
Form 144 AGIOS PHARMACEUTICALS, Filed by: Jones Cecilia
April 2, 2026 4:09 PM - SEC Filing
Form 144 AGIOS PHARMACEUTICALS, Filed by: Viswanadhan Krishnan
April 2, 2026 4:07 PM - SEC Filing
Form 144 AGIOS PHARMACEUTICALS, Filed by: Milanova Tsveta
April 2, 2026 4:06 PM - SEC Filing
Form 144 AGIOS PHARMACEUTICALS, Filed by: Gheuens Sarah
April 2, 2026 4:05 PM - SEC Filing
Form 144 AGIOS PHARMACEUTICALS, Filed by: Burns James William
April 2, 2026 4:02 PM - SEC Filing
Agios Pharma (AGIO) PT Raised to $32 at Goldman Sachs
April 1, 2026 6:17 AM - StreetInsider
Leerink on Fulcrum Therapeutics (FULC): 'We believe this is a positive sign for FULC'
March 31, 2026 1:08 PM - StreetInsider
Agios Pharma (AGIO) PT Raised to $44 at BofA Securities
March 31, 2026 9:48 AM - StreetInsider
Stifel: 'we think FULC as a soon-to-be ph3 SCD company is significantly under-appreciated'
March 31, 2026 8:54 AM - StreetInsider
Truist Securities stays Buy on Agios Pharma (AGIO) as co seeks accelerated approval for mitapivat
March 31, 2026 8:33 AM - StreetInsider
Agios plans mitapivat sickle cell disease filing after FDA meeting
March 31, 2026 7:01 AM - StreetInsider
Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA
March 31, 2026 7:00 AM - Globe NewsWire
Form SCHEDULE 13G/A AGIOS PHARMACEUTICALS, Filed by: VANGUARD GROUP INC
March 26, 2026 3:13 PM - SEC Filing
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact The Gross Law Firm Regarding an Ongoing Investigation
March 17, 2026 9:02 AM - PR NewsWire
Full Article List
